Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a phone app beat fatty liver? new trial tests digital coaching

NCT ID NCT07007741

Disease control Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This trial tests whether a smartphone app and remote diet/exercise coaching can help people with non-alcoholic fatty liver disease lose weight and reduce liver fat. 120 participants will either get standard lifestyle advice or use the app with daily meal tracking, weekly recipe adjustments, and one-on-one Q&A with a dietitian. The study is active but not recruiting, and results could show if digital tools can improve liver health at scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fatty Liver Data Analysis and Management Software (smartphone app with remote diet/exercise coaching)
What this could lead to
If it works, this could provide an effective, scalable way for doctors to help people with fatty liver lose weight and reduce liver fat through remote lifestyle coaching.
What could go wrong
This is a small, early-stage trial (120 people) testing a software tool, not a drug. The results may not apply to everyone, and the app's success depends on daily user engagement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

141 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * NAFLD patient (CAP value \>248 (dB/m)) * Age 18-65 years old, 24kg/m2 ≤ BMI ≤ 35kg/m2 * Must be able to use smartphone Exclusion Criteria: * Inherited metabolic or autoimmune liver disease * Drug/toxic/alcoholic/biliary liver injury, cirrhosis or any end-stage liver disease * Hepatic or extrahepatic malignant tumours * Pregnant and lactating women * Patients considered ineligible by the investigator's clinical judgment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonalcoholic fatty liver are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fatty liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonalcoholic fatty liver Steatohepatitis, nonalcoholic

Contacts and locations

Locations

  • XinHua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200082, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.